Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Table 2 Adverse events of patients in 12 mg/day group (the 2/1 schedule)

Adverse events	Grade 1/2				Grade 3
	First 2 cycles		All cycles		First 2 cycles		All cycles
	No. of patients	%	No. of patients	%	No. of patients	%	No. of patients	%
Occurred at least one time	21	100	21	100	2	10	6	29
Hand-foot skin reaction	4	19	10	48	0	0	1	5
Rash	4	19	6	29	0	0	0	0
Hypertension	5	24	5	24	0	0	2	10
Proteinuria	5	24	14	67	0	0	0	0
Triglyceride elevation	6	29	11	52	1	5	2	10
Total cholesterol elevation	6	29	13	62	0	0	0	0
Hypothyroidism	8	38	12	57	0	0	0	0
Hyperthyroidism	2	10	2	10	0	0	0	0
ALT elevation	6	29	10	48	0	0	0	0
AST elevation	4	19	9	43	0	0	0	0
Creatinine elevation	1	5	2	10	0	0	0	0
Total bilirubin elevation	5	24	8	38	0	0	0	0
Lipase elevation	1	5	5	24	1	5	1	5
Serum amylase	4	19	9	43	0	0	0	0
Myocardial enzymes abnormal	2	10	3	14	0	0	0	0
Leukopenia	3	14	6	29	0	0	0	0
Neutropenia	0	0	2	10	0	0	0	0
Thrombocytopenia	0	0	2	10	0	0	0	0
Hemorrhage	0	0	1	5	0	0	0	0
Urine occult blood	5	24	8	38	0	0	0	0
Fatigue	5	24	7	33	0	0	0	0
Diarrhea	6	29	7	33	0	0	0	0
Hoarseness	3	14	5	24	0	0	0	0
Nausea	3	14	3	14	0	0	0	0
Inappetence	1	5	2	10	0	0	0	0
Toothache	1	5	4	19	0	0	0	0
Pharyngalgia	1	5	4	19	0	0	0	0
Premature beat	0	0	1	5	0	0	0	0